TAVALISSE Comprimé

País: Canadá

Idioma: francés

Fuente: Health Canada

Ingredientes activos:

Fostamatinib (Fostamatinib disodique)

Disponible desde:

MEDISON PHARMA CANADA INC.

Código ATC:

B02BX09

Designación común internacional (DCI):

FOSTAMATINIB

Dosis:

150MG

formulario farmacéutico:

Comprimé

Composición:

Fostamatinib (Fostamatinib disodique) 150MG

Vía de administración:

Orale

Unidades en paquete:

15G/50G

tipo de receta:

Prescription

Área terapéutica:

HEMOSTATICS

Resumen del producto:

Numéro de groupe d'ingrédients actifs (GIA) :0162598001; AHFS:

Estado de Autorización:

APPROUVÉ

Fecha de autorización:

2021-07-15

Ficha técnica

0212*53,( '(352'8,7
2035(117/(65(16(,*1(0(176685/( 0e',
0(17'(67,1e6
837,(17
3U
79 /,66(
0
RPSULPpVGH)RVWDPDWLQLE
IRVWDPDWLQLE
P
PVRXVIRUPHGHIRVWDPDWLQLEGLVRGLTXHKH[DKGUDWp
QWLKpPRUUDLTXHV
RGH
7
%%;
7 9/,66(
0'
HVW XQHPDUTXHGpSRVpHGH 5L
HO
3KDUPDFHXWLFDOV ,QFXWLOLVpHVRXVOLFHQFH
SDU0HGLVRQ 3KDUPD
DQDGD ,QF
1
R
GHFRQWU
OHGHODSUpVHQWDWLRQ
'DWHGDSSUREDWLRQ LQLWLDOH
QRYHPEUH
'DWHGH UpYLVLRQ
MXLOOHW
0HGLVRQ3KDUPDDQDGD,QF
0RXQW 3OHDVDQW5RDG
7RURQWR 2QWDULR
01 7
3D H
GH
5e (17(602,),
7,216 ,03257 17(6(/e7,48(77(
1RQDSSOLFDEOH
7%/(
(6 0 7,5(6
357,( ,
5(16(,*1(0(1763285 /(352)(66,211(/( /617e
,1 ,7,216
3DWLHQWVSpGLDWULTXHV
3DWLHQWVpULDWULTXHV
2175( ,1,
7,216
3262/2*,((7
0,1,675 7,21
RQVLGpUDWLRQVSRVROR LTXHV
'RVHUHFRPPDQGpHHWPRGLILFDWLRQSRVROR LTXH
GPLQLVWUDWLRQ
5HFRQVWLWXWLRQ
'RVHRXEOLpH
68526*(
)250(6
(3262/2*,(21 (1757,21620326,7,21(7
21 ,7,211(0(17
0,6(6 (1 *5( (7 35e
87,216
3RSXODWLRQVSDUWLFXOLqUHV
)HPPHV HQFHLQWHV
OODLWHPHQW
(QIDQWV
3HUVRQQHV kpHV
())(76,1e6,5%/(6
SHUoX GHVHIIHWV LQGpVLUDEOHV
(IIHWVLQGpVLUDEOHV ORUV GHVpWXGHV FOLQLTXHV
(IIHWV LQGpVLUDEOHV SHX FRXUDQWV LGHQWLILpVORUVGHVHVVDLVFOLQLTXHV
5pVXOWDWV GHODERUDWRLUHDQRUPDX[
KpPDWROR LH FKLPLHFOLQLTXH HWDXWUHV
GRQQpHV TXDQWLWDWLYHV
(IIHWV LQGpVLUDEOHVORUVGHVpWXGHVFOLQLTXHVSDWLHQWVSpGLDWULTXHV
(IIHWV LQGpVLUDEOHV LGHQWLILpVDSUqVODPLVH HQPDUFKp
,17(5
7,216
9(
875(60e,
0(176
SHUoX
,QWHUDFWLRQVPpGLFDPHQW PpGLFDPHQW
,QWHUDFWLRQVPpGLFDPHQW DOLPHQW
,QWHUDFWLRQVPpGLFDPHQW
SODQWHPpGLFLQDOH
,QWHUDFWLRQV HQWUHOHPpGLFDPHQWHWOHVHVVDLVHQODERUDWRLUH
02(
7,21(7 3 50
2/2*,(/,1,48(
0pFDQLVPHGDFWLRQ
3KDUPDFRG QDPLTXH
3KDUPDFRFLQpWLTXH
216(597,21 67 %,/,7e (7 e/,0,1 7,21
3D H
GH
,167587,216 63e ,/(6(0 1,38/ 7,21
357,( ,,
,1)250 7,216 6,(17,),48(6
211e(6350 (87,48(6
e78(6/,1,48(6
RQFHSWLRQGHOHVVDLHW DVSHFWV GpPR UDSKLTXHVGHOpWXGH
5pVXOWDWVGHVpWXGHV
72 ,
2/2*,( 121/,1,48(
5(16(,*1(0(176685/(0e, 0(17(67,1e6
8 37,(176
3D H
GH
357,( ,
5(16(,*1(0(176 3285/( 352)(66,211(/
(/ 6 17e
,1 ,7,216
79 /,66(
0'
IRVWDPDWLQLEGLVRGLTXHKH[DKGUDWp HVW LQGLTXpSRXUOHWUDLWHPHQW GHOD
WKURPERFWRSpQLHFKH]